CYTK vs NVS
Cytokinetics vs Novartis AG — AI-powered side-by-side comparison
CYTK
Cytokinetics
52
Watch
VS
| Metric | CYTK | NVS |
|---|
| AI Score |
52
|
72
|
| Price |
$79.43
|
$157.51
|
| P/E Ratio |
-10.74×
|
24.26×
|
| ROE |
119.0%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
85.0%
|
74.3%
|
| Debt / Equity |
-7.32×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
52.8
|
63.1
|
| Beta |
0.376
|
0.462
|
| Expected Upside |
+3.3%
|
+0.3%
|
AI Committee View
Current Innellis committee reasoning for CYTK versus NVS.
NVS leads by 20 points.
NVS scores 72/100 (Buy) versus CYTK at 52/100 (Watch).
CYTK Committee View
60% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 15.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 15.7x prices in significant intangible value — Value
- ROE of only -131.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -21.1% YoY -- this is not a growth story right now — Growth
NVS Committee View
100% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Risk/reward is unfavorable: 9.2% downside vs 0.3% upside.